The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oncology Companion Diagnostic Market Research Report 2025
Synopsis
A companion diagnostic is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
The global Oncology Companion Diagnostic market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oncology Companion Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Companion Diagnostic.
Report Scope
The Oncology Companion Diagnostic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Companion Diagnostic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Companion Diagnostic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agilent Technologies, Inc.
Illumina, Inc.
Qiagen N.V.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
ARUP Laboratories
Abbott
Myriad Genetics, Inc.
bioMérieux SA
Invivoscribe, Inc.
Segment by Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
Segment by Application
Hospital
Pathology/Diagnostic Laboratory
Academic Medical Center
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Companion Diagnostic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A companion diagnostic is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
The global Oncology Companion Diagnostic market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oncology Companion Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Companion Diagnostic.
Report Scope
The Oncology Companion Diagnostic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Companion Diagnostic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Companion Diagnostic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agilent Technologies, Inc.
Illumina, Inc.
Qiagen N.V.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
ARUP Laboratories
Abbott
Myriad Genetics, Inc.
bioMérieux SA
Invivoscribe, Inc.
Segment by Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
Segment by Application
Hospital
Pathology/Diagnostic Laboratory
Academic Medical Center
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Companion Diagnostic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Companion Diagnostic Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Next-Generation Sequencing (NGS)
1.2.4 Immunohistochemistry (IHC)
1.2.5 In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Oncology Companion Diagnostic Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Pathology/Diagnostic Laboratory
1.3.4 Academic Medical Center
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Companion Diagnostic Market Perspective (2019-2030)
2.2 Oncology Companion Diagnostic Growth Trends by Region
2.2.1 Global Oncology Companion Diagnostic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oncology Companion Diagnostic Historic Market Size by Region (2019-2024)
2.2.3 Oncology Companion Diagnostic Forecasted Market Size by Region (2025-2030)
2.3 Oncology Companion Diagnostic Market Dynamics
2.3.1 Oncology Companion Diagnostic Industry Trends
2.3.2 Oncology Companion Diagnostic Market Drivers
2.3.3 Oncology Companion Diagnostic Market Challenges
2.3.4 Oncology Companion Diagnostic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Companion Diagnostic Players by Revenue
3.1.1 Global Top Oncology Companion Diagnostic Players by Revenue (2019-2024)
3.1.2 Global Oncology Companion Diagnostic Revenue Market Share by Players (2019-2024)
3.2 Global Oncology Companion Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncology Companion Diagnostic Revenue
3.4 Global Oncology Companion Diagnostic Market Concentration Ratio
3.4.1 Global Oncology Companion Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Companion Diagnostic Revenue in 2023
3.5 Oncology Companion Diagnostic Key Players Head office and Area Served
3.6 Key Players Oncology Companion Diagnostic Product Solution and Service
3.7 Date of Enter into Oncology Companion Diagnostic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Companion Diagnostic Breakdown Data by Type
4.1 Global Oncology Companion Diagnostic Historic Market Size by Type (2019-2024)
4.2 Global Oncology Companion Diagnostic Forecasted Market Size by Type (2025-2030)
5 Oncology Companion Diagnostic Breakdown Data by Application
5.1 Global Oncology Companion Diagnostic Historic Market Size by Application (2019-2024)
5.2 Global Oncology Companion Diagnostic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oncology Companion Diagnostic Market Size (2019-2030)
6.2 North America Oncology Companion Diagnostic Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oncology Companion Diagnostic Market Size by Country (2019-2024)
6.4 North America Oncology Companion Diagnostic Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncology Companion Diagnostic Market Size (2019-2030)
7.2 Europe Oncology Companion Diagnostic Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oncology Companion Diagnostic Market Size by Country (2019-2024)
7.4 Europe Oncology Companion Diagnostic Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncology Companion Diagnostic Market Size (2019-2030)
8.2 Asia-Pacific Oncology Companion Diagnostic Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2019-2024)
8.4 Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncology Companion Diagnostic Market Size (2019-2030)
9.2 Latin America Oncology Companion Diagnostic Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oncology Companion Diagnostic Market Size by Country (2019-2024)
9.4 Latin America Oncology Companion Diagnostic Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Companion Diagnostic Market Size (2019-2030)
10.2 Middle East & Africa Oncology Companion Diagnostic Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2019-2024)
10.4 Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent Technologies, Inc.
11.1.1 Agilent Technologies, Inc. Company Detail
11.1.2 Agilent Technologies, Inc. Business Overview
11.1.3 Agilent Technologies, Inc. Oncology Companion Diagnostic Introduction
11.1.4 Agilent Technologies, Inc. Revenue in Oncology Companion Diagnostic Business (2019-2024)
11.1.5 Agilent Technologies, Inc. Recent Development
11.2 Illumina, Inc.
11.2.1 Illumina, Inc. Company Detail
11.2.2 Illumina, Inc. Business Overview
11.2.3 Illumina, Inc. Oncology Companion Diagnostic Introduction
11.2.4 Illumina, Inc. Revenue in Oncology Companion Diagnostic Business (2019-2024)
11.2.5 Illumina, Inc. Recent Development
11.3 Qiagen N.V.
11.3.1 Qiagen N.V. Company Detail
11.3.2 Qiagen N.V. Business Overview
11.3.3 Qiagen N.V. Oncology Companion Diagnostic Introduction
11.3.4 Qiagen N.V. Revenue in Oncology Companion Diagnostic Business (2019-2024)
11.3.5 Qiagen N.V. Recent Development
11.4 Thermo Fisher Scientific Inc.
11.4.1 Thermo Fisher Scientific Inc. Company Detail
11.4.2 Thermo Fisher Scientific Inc. Business Overview
11.4.3 Thermo Fisher Scientific Inc. Oncology Companion Diagnostic Introduction
11.4.4 Thermo Fisher Scientific Inc. Revenue in Oncology Companion Diagnostic Business (2019-2024)
11.4.5 Thermo Fisher Scientific Inc. Recent Development
11.5 F. Hoffmann-La Roche Ltd.
11.5.1 F. Hoffmann-La Roche Ltd. Company Detail
11.5.2 F. Hoffmann-La Roche Ltd. Business Overview
11.5.3 F. Hoffmann-La Roche Ltd. Oncology Companion Diagnostic Introduction
11.5.4 F. Hoffmann-La Roche Ltd. Revenue in Oncology Companion Diagnostic Business (2019-2024)
11.5.5 F. Hoffmann-La Roche Ltd. Recent Development
11.6 ARUP Laboratories
11.6.1 ARUP Laboratories Company Detail
11.6.2 ARUP Laboratories Business Overview
11.6.3 ARUP Laboratories Oncology Companion Diagnostic Introduction
11.6.4 ARUP Laboratories Revenue in Oncology Companion Diagnostic Business (2019-2024)
11.6.5 ARUP Laboratories Recent Development
11.7 Abbott
11.7.1 Abbott Company Detail
11.7.2 Abbott Business Overview
11.7.3 Abbott Oncology Companion Diagnostic Introduction
11.7.4 Abbott Revenue in Oncology Companion Diagnostic Business (2019-2024)
11.7.5 Abbott Recent Development
11.8 Myriad Genetics, Inc.
11.8.1 Myriad Genetics, Inc. Company Detail
11.8.2 Myriad Genetics, Inc. Business Overview
11.8.3 Myriad Genetics, Inc. Oncology Companion Diagnostic Introduction
11.8.4 Myriad Genetics, Inc. Revenue in Oncology Companion Diagnostic Business (2019-2024)
11.8.5 Myriad Genetics, Inc. Recent Development
11.9 bioMérieux SA
11.9.1 bioMérieux SA Company Detail
11.9.2 bioMérieux SA Business Overview
11.9.3 bioMérieux SA Oncology Companion Diagnostic Introduction
11.9.4 bioMérieux SA Revenue in Oncology Companion Diagnostic Business (2019-2024)
11.9.5 bioMérieux SA Recent Development
11.10 Invivoscribe, Inc.
11.10.1 Invivoscribe, Inc. Company Detail
11.10.2 Invivoscribe, Inc. Business Overview
11.10.3 Invivoscribe, Inc. Oncology Companion Diagnostic Introduction
11.10.4 Invivoscribe, Inc. Revenue in Oncology Companion Diagnostic Business (2019-2024)
11.10.5 Invivoscribe, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Oncology Companion Diagnostic Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Polymerase Chain Reaction (PCR)
Table 3. Key Players of Next-Generation Sequencing (NGS)
Table 4. Key Players of Immunohistochemistry (IHC)
Table 5. Key Players of In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Table 6. Key Players of Others
Table 7. Global Oncology Companion Diagnostic Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Oncology Companion Diagnostic Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Oncology Companion Diagnostic Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Oncology Companion Diagnostic Market Share by Region (2019-2024)
Table 11. Global Oncology Companion Diagnostic Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Oncology Companion Diagnostic Market Share by Region (2025-2030)
Table 13. Oncology Companion Diagnostic Market Trends
Table 14. Oncology Companion Diagnostic Market Drivers
Table 15. Oncology Companion Diagnostic Market Challenges
Table 16. Oncology Companion Diagnostic Market Restraints
Table 17. Global Oncology Companion Diagnostic Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Oncology Companion Diagnostic Market Share by Players (2019-2024)
Table 19. Global Top Oncology Companion Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Companion Diagnostic as of 2023)
Table 20. Ranking of Global Top Oncology Companion Diagnostic Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Oncology Companion Diagnostic Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Oncology Companion Diagnostic Product Solution and Service
Table 24. Date of Enter into Oncology Companion Diagnostic Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Oncology Companion Diagnostic Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Oncology Companion Diagnostic Revenue Market Share by Type (2019-2024)
Table 28. Global Oncology Companion Diagnostic Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Oncology Companion Diagnostic Revenue Market Share by Type (2025-2030)
Table 30. Global Oncology Companion Diagnostic Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Oncology Companion Diagnostic Revenue Market Share by Application (2019-2024)
Table 32. Global Oncology Companion Diagnostic Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Oncology Companion Diagnostic Revenue Market Share by Application (2025-2030)
Table 34. North America Oncology Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Oncology Companion Diagnostic Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Oncology Companion Diagnostic Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Oncology Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Oncology Companion Diagnostic Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Oncology Companion Diagnostic Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Oncology Companion Diagnostic Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Oncology Companion Diagnostic Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Oncology Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Oncology Companion Diagnostic Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Oncology Companion Diagnostic Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Oncology Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Oncology Companion Diagnostic Market Size by Country (2025-2030) & (US$ Million)
Table 49. Agilent Technologies, Inc. Company Detail
Table 50. Agilent Technologies, Inc. Business Overview
Table 51. Agilent Technologies, Inc. Oncology Companion Diagnostic Product
Table 52. Agilent Technologies, Inc. Revenue in Oncology Companion Diagnostic Business (2019-2024) & (US$ Million)
Table 53. Agilent Technologies, Inc. Recent Development
Table 54. Illumina, Inc. Company Detail
Table 55. Illumina, Inc. Business Overview
Table 56. Illumina, Inc. Oncology Companion Diagnostic Product
Table 57. Illumina, Inc. Revenue in Oncology Companion Diagnostic Business (2019-2024) & (US$ Million)
Table 58. Illumina, Inc. Recent Development
Table 59. Qiagen N.V. Company Detail
Table 60. Qiagen N.V. Business Overview
Table 61. Qiagen N.V. Oncology Companion Diagnostic Product
Table 62. Qiagen N.V. Revenue in Oncology Companion Diagnostic Business (2019-2024) & (US$ Million)
Table 63. Qiagen N.V. Recent Development
Table 64. Thermo Fisher Scientific Inc. Company Detail
Table 65. Thermo Fisher Scientific Inc. Business Overview
Table 66. Thermo Fisher Scientific Inc. Oncology Companion Diagnostic Product
Table 67. Thermo Fisher Scientific Inc. Revenue in Oncology Companion Diagnostic Business (2019-2024) & (US$ Million)
Table 68. Thermo Fisher Scientific Inc. Recent Development
Table 69. F. Hoffmann-La Roche Ltd. Company Detail
Table 70. F. Hoffmann-La Roche Ltd. Business Overview
Table 71. F. Hoffmann-La Roche Ltd. Oncology Companion Diagnostic Product
Table 72. F. Hoffmann-La Roche Ltd. Revenue in Oncology Companion Diagnostic Business (2019-2024) & (US$ Million)
Table 73. F. Hoffmann-La Roche Ltd. Recent Development
Table 74. ARUP Laboratories Company Detail
Table 75. ARUP Laboratories Business Overview
Table 76. ARUP Laboratories Oncology Companion Diagnostic Product
Table 77. ARUP Laboratories Revenue in Oncology Companion Diagnostic Business (2019-2024) & (US$ Million)
Table 78. ARUP Laboratories Recent Development
Table 79. Abbott Company Detail
Table 80. Abbott Business Overview
Table 81. Abbott Oncology Companion Diagnostic Product
Table 82. Abbott Revenue in Oncology Companion Diagnostic Business (2019-2024) & (US$ Million)
Table 83. Abbott Recent Development
Table 84. Myriad Genetics, Inc. Company Detail
Table 85. Myriad Genetics, Inc. Business Overview
Table 86. Myriad Genetics, Inc. Oncology Companion Diagnostic Product
Table 87. Myriad Genetics, Inc. Revenue in Oncology Companion Diagnostic Business (2019-2024) & (US$ Million)
Table 88. Myriad Genetics, Inc. Recent Development
Table 89. bioMérieux SA Company Detail
Table 90. bioMérieux SA Business Overview
Table 91. bioMérieux SA Oncology Companion Diagnostic Product
Table 92. bioMérieux SA Revenue in Oncology Companion Diagnostic Business (2019-2024) & (US$ Million)
Table 93. bioMérieux SA Recent Development
Table 94. Invivoscribe, Inc. Company Detail
Table 95. Invivoscribe, Inc. Business Overview
Table 96. Invivoscribe, Inc. Oncology Companion Diagnostic Product
Table 97. Invivoscribe, Inc. Revenue in Oncology Companion Diagnostic Business (2019-2024) & (US$ Million)
Table 98. Invivoscribe, Inc. Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oncology Companion Diagnostic Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Oncology Companion Diagnostic Market Share by Type: 2023 VS 2030
Figure 3. Polymerase Chain Reaction (PCR) Features
Figure 4. Next-Generation Sequencing (NGS) Features
Figure 5. Immunohistochemistry (IHC) Features
Figure 6. In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH) Features
Figure 7. Others Features
Figure 8. Global Oncology Companion Diagnostic Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Oncology Companion Diagnostic Market Share by Application: 2023 VS 2030
Figure 10. Hospital Case Studies
Figure 11. Pathology/Diagnostic Laboratory Case Studies
Figure 12. Academic Medical Center Case Studies
Figure 13. Oncology Companion Diagnostic Report Years Considered
Figure 14. Global Oncology Companion Diagnostic Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Oncology Companion Diagnostic Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Oncology Companion Diagnostic Market Share by Region: 2023 VS 2030
Figure 17. Global Oncology Companion Diagnostic Market Share by Players in 2023
Figure 18. Global Top Oncology Companion Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Companion Diagnostic as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Oncology Companion Diagnostic Revenue in 2023
Figure 20. North America Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Oncology Companion Diagnostic Market Share by Country (2019-2030)
Figure 22. United States Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Oncology Companion Diagnostic Market Share by Country (2019-2030)
Figure 26. Germany Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Oncology Companion Diagnostic Market Share by Region (2019-2030)
Figure 34. China Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Oncology Companion Diagnostic Market Share by Country (2019-2030)
Figure 42. Mexico Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Oncology Companion Diagnostic Market Share by Country (2019-2030)
Figure 46. Turkey Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Oncology Companion Diagnostic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Agilent Technologies, Inc. Revenue Growth Rate in Oncology Companion Diagnostic Business (2019-2024)
Figure 49. Illumina, Inc. Revenue Growth Rate in Oncology Companion Diagnostic Business (2019-2024)
Figure 50. Qiagen N.V. Revenue Growth Rate in Oncology Companion Diagnostic Business (2019-2024)
Figure 51. Thermo Fisher Scientific Inc. Revenue Growth Rate in Oncology Companion Diagnostic Business (2019-2024)
Figure 52. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Oncology Companion Diagnostic Business (2019-2024)
Figure 53. ARUP Laboratories Revenue Growth Rate in Oncology Companion Diagnostic Business (2019-2024)
Figure 54. Abbott Revenue Growth Rate in Oncology Companion Diagnostic Business (2019-2024)
Figure 55. Myriad Genetics, Inc. Revenue Growth Rate in Oncology Companion Diagnostic Business (2019-2024)
Figure 56. bioMérieux SA Revenue Growth Rate in Oncology Companion Diagnostic Business (2019-2024)
Figure 57. Invivoscribe, Inc. Revenue Growth Rate in Oncology Companion Diagnostic Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
